A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

被引：3

作者：

Mohan, Sanjay R. ^{[1
]}

Oh, Stephen T. ^{[2
]}

Ali, Haris ^{[3
]}

Hunter, Anthony M. ^{[4
]}

Palandri, Francesca ^{[5
]}

Lamothe, Betty ^{[6
]}

Cui, Yi ^{[6
]}

Seguy, Francis ^{[7
]}

McBride, Amanda ^{[6
]}

Savona, Michael Robert ^{[8
]}

Kiladjian, Jean-Jacques ^{[9
]}

Verstovsek, Srdan ^{[10
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[3] City Hope Med Ctr, Duarte, CA USA

[4] Emory Univ, Sch Med, Atlanta, GA USA

[5] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[6] Incyte Corp, Wilmington, DE USA

[7] Incyte Biosci Int Sarl, Morges, Switzerland

[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[9] Hop St Louis, Paris, France

[10] Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-169210

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3943 / 3944

页数：2

共 50 条

[31] Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study
Palandri, Francesca
Elli, Elena M.
Morsia, Erika
Benevolo, Giulia
Tiribelli, Mario
Beggiato, Eloise
Bonifacio, Massimiliano
Farina, Mirko
Martino, Bruno
Caocci, Giovanni
Pugliese, Novella
Tieghi, Alessia
Crugnola, Monica
Binotto, Gianni
Cavazzini, Francesco
Abruzzese, Elisabetta
Iurlo, Alessandra
Isidori, Alessandro
Bosi, Costanza
Guglielmana, Veronica
Venturi, Marta
Dedola, Alessandra
Loffredo, Michele
Fontana, Gabriele
Duminuco, Andrea
Moioli, Alessia
Tosoni, Luca
Scalzulli, Emilia
Cattaneo, Daniele
Lemoli, Roberto M.
Cilloni, Daniela
Bocchia, Monica
Pane, Fabrizio
Heidel, Florian H.
Vianelli, Nicola
Cavo, Michele
Palumbo, Giuseppe A.
Branzanti, Filippo
Breccia, Massimo
CANCER, 2024, 130 (24) : 4257 - 4266
[32] COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1-, INTERMEDIATE-2-, AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY
Passamonti, F.
Gupta, V.
Martino, B.
Foltz, L.
Zaritksey, A.
Al-Ali, H. K.
Tavares, R.
Maffioli, M.
Raanani, P.
Giraldo, P.
Griesshammer, M.
Bouard, C.
Ronco, J. Perez
Tiwari, R.
Vannucchi, A. M.
HAEMATOLOGICA, 2017, 102 : 548 - 548
[33] Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia
Bose, Prithviraj
Daver, Naval
Pemmaraju, Naveen
Jabbour, Elias J.
Estrov, Zeev
Pike, Allison
Huynh-Lu, Julie
Nguyen-Cao, Madeleine
Wang, Xuemei
Zhou, Lingsha
Pierce, Sherry
Kantarjian, Hagop M.
Verstovsek, Srdan
BLOOD, 2017, 130
[34] Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
Harrison, Claire N.
Vannucchi, Alessandro M.
Platzbecker, Uwe
Cervantes, Francisco
Gupta, Vikas
Lavie, David
Passamonti, Francesco
Winton, Elliott F.
Dong, Hua
Kawashima, Jun
Maltzman, Julia D.
Kiladjian, Jean-Jacques
Verstovsek, Srdan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials
Al-Ali, Haifa
Mesa, Ruben
Hamer-Maansson, J. E.
Braunstein, Evan
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S404 - S404
[36] A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Masarova, Lucia
Verstovsek, Srdan
Hidalgo-Lopez, Juliana E.
Pemmaraju, Naveen
Bose, Prithviraj
Estrov, Zeev
Jabbour, Elias J.
Ravandi-Kashani, Farhad
Takahashi, Koichi
Cortes, Jorge E.
Ning, Jing
Ohanian, Maro
Alvarado, Yesid
Zhou, Lingsha
Pierce, Sherry
Gergis, Romany
Patel, Keyur P.
Luthra, Rajyalakshmi
Kadia, Tapan M.
DiNardo, Courtney D.
Borthakur, Gautam
Bhalla, Kapil
Garcia-Manero, Guillermo
Bueso-Ramos, Carlos E.
Kantarjian, Hagop M.
Daver, Naval
BLOOD, 2018, 132 (16) : 1664 - 1674
[37] SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (≥75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY
Raanani, P.
Gupta, V.
Sadjadian, P.
Al-Ali, H. K.
Giraldo, P.
Guglielmelli, P.
Foltz, L.
Tavares, R.
Zaritksey, A.
Bouard, C.
Ronco, J. Perez
Tiwari, R.
Martino, B.
HAEMATOLOGICA, 2017, 102 : 281 - +
[38] PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
Talpaz, M.
Mascarenhas, J.
Hoffman, R.
Gerds, A. T.
Stein, B.
Gupta, V.
Szoke, A.
Drummond, M.
Pristupa, A.
Granston, T.
Daly, R.
Al-Fayoumi, S.
Callahan, J. A.
Singer, J. W.
Gotlib, J.
Jamieson, C.
Harrison, C.
Mesa, R.
Verstovsek, S.
HAEMATOLOGICA, 2017, 102 : 279 - 280
[39] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
Rampal, Raajit K.
Verstovsek, Srdan
Devlin, Sean M.
King, Amber C.
Stein, Eytan M.
Pemmaraju, Naveen
Mauro, Michael J.
Kadia, Tapan M.
Montalban-Bravo, Guillermo
Alvarez, Kelsey
Ard, Nicole
Goodman, Tawni
Taylor, Bria
Bose, Prithviraj
BLOOD, 2019, 134
[40] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
Gowin, Krisstina L.
Dueck, Amylou C.
Mascarenhas, John O.
Hoffman, Ronald
Reeder, Craig B.
Camoriano, John
Gano, Katherine
Ghurye, Vineta
Reddy, Sravan Nagi
Koenig, Patricia
Fauble, Veena
Tibes, Raoul
Mesa, Ruben
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →